PE20190104A1 - Antigenos y anticuerpos de chagas y composiciones, metodos y usos de los mismos - Google Patents
Antigenos y anticuerpos de chagas y composiciones, metodos y usos de los mismosInfo
- Publication number
- PE20190104A1 PE20190104A1 PE2018001985A PE2018001985A PE20190104A1 PE 20190104 A1 PE20190104 A1 PE 20190104A1 PE 2018001985 A PE2018001985 A PE 2018001985A PE 2018001985 A PE2018001985 A PE 2018001985A PE 20190104 A1 PE20190104 A1 PE 20190104A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- antigens
- compositions
- chagas
- antibodies
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 241000223104 Trypanosoma Species 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/005—Trypanosoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Referido a antigenos de Trypanosoma cuya secuencia es seleccionada de SEC ID NO: 6, SEC ID NO: 9, SEC ID NO: 5, SEC ID NO: 7, SEC ID NO: 8, SEC ID NO: 11, SEC ID NO: 1, SEC ID NO: 2, SEC ID NO: 3, SEC ID NO: 4, SEC ID NO: 10 o SEC ID NO: 12, o un peptido con 75% de identidad de aminoacidos de las secuencias citadas. Tambien se refiere a composiciones inmunogenicas que comprenden uno o mas de los antigenos descritos para tratar enfermedades basadas en Trypanosoma
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662322770P | 2016-04-14 | 2016-04-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20190104A1 true PE20190104A1 (es) | 2019-01-15 |
Family
ID=58671580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018001985A PE20190104A1 (es) | 2016-04-14 | 2017-04-18 | Antigenos y anticuerpos de chagas y composiciones, metodos y usos de los mismos |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10973897B2 (es) |
| EP (1) | EP3442569A1 (es) |
| JP (1) | JP2019513797A (es) |
| KR (1) | KR20190039022A (es) |
| CN (2) | CN109310747B (es) |
| AU (1) | AU2017248680A1 (es) |
| BR (1) | BR112018071108A2 (es) |
| CA (1) | CA3020856A1 (es) |
| CL (2) | CL2018002932A1 (es) |
| CO (1) | CO2018012295A2 (es) |
| CU (1) | CU20180127A7 (es) |
| EC (1) | ECSP18079073A (es) |
| MX (1) | MX2018012504A (es) |
| NI (1) | NI201800105A (es) |
| PE (1) | PE20190104A1 (es) |
| RU (1) | RU2018139865A (es) |
| SG (1) | SG11201808915YA (es) |
| WO (1) | WO2017178660A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020144465A1 (en) * | 2019-01-07 | 2020-07-16 | Genome Research Limited | Novel trypanosomal vaccine |
| WO2020144464A1 (en) | 2019-01-07 | 2020-07-16 | Genome Research Limited | Novel trypanosomal vaccine |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2731370A1 (de) * | 1977-07-12 | 1979-01-25 | Behringwerke Ag | Chagas impfstoff und verfahren zu dessen herstellung |
| ES2169995B1 (es) | 2000-04-17 | 2003-12-01 | Leti Lab | Composicion a base de la proteina lip2a y su uso en la preparacion de un medicamento para suscitar una respuesta inmune contra un antigeno. |
| US20040057958A1 (en) | 2002-05-17 | 2004-03-25 | Waggoner David W. | Immunogenicity-enhancing carriers and compositions thereof and methods of using the same |
| FR2952382B1 (fr) * | 2009-11-10 | 2011-11-25 | Univ Victor Segalen Bordeaux 2 | Vaccins et diagnostics contre les trypanosomoses animales africaines |
| SA110310855B1 (ar) * | 2009-11-13 | 2014-09-16 | Laboratories Leti S L Unipersonal | استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي |
| BR112015032978B1 (pt) | 2013-07-02 | 2022-08-16 | Institut De Recherche Pour Le Développement | Método de diagnóstico para a detecção de anticorpos indicativos de leishmania sul americana e kit de diagnóstico para detecção de anticorpos antileishmaniose |
| US9566320B2 (en) * | 2013-09-24 | 2017-02-14 | The Board Of Regents Of The University Of Texas System | Mucin-associated surface protein as vaccine against Chagas disease |
-
2017
- 2017-04-14 US US15/487,935 patent/US10973897B2/en active Active
- 2017-04-18 JP JP2018554466A patent/JP2019513797A/ja active Pending
- 2017-04-18 EP EP17721544.9A patent/EP3442569A1/en active Pending
- 2017-04-18 BR BR112018071108-0A patent/BR112018071108A2/pt not_active Application Discontinuation
- 2017-04-18 KR KR1020187032828A patent/KR20190039022A/ko not_active Withdrawn
- 2017-04-18 CN CN201780037260.8A patent/CN109310747B/zh active Active
- 2017-04-18 CU CU2018000127A patent/CU20180127A7/es unknown
- 2017-04-18 SG SG11201808915YA patent/SG11201808915YA/en unknown
- 2017-04-18 RU RU2018139865A patent/RU2018139865A/ru not_active Application Discontinuation
- 2017-04-18 MX MX2018012504A patent/MX2018012504A/es unknown
- 2017-04-18 WO PCT/EP2017/059189 patent/WO2017178660A1/en not_active Ceased
- 2017-04-18 AU AU2017248680A patent/AU2017248680A1/en not_active Abandoned
- 2017-04-18 CA CA3020856A patent/CA3020856A1/en active Pending
- 2017-04-18 PE PE2018001985A patent/PE20190104A1/es not_active Application Discontinuation
- 2017-04-18 CN CN202211370674.1A patent/CN116059330A/zh active Pending
-
2018
- 2018-10-12 NI NI201800105A patent/NI201800105A/es unknown
- 2018-10-12 CL CL2018002932A patent/CL2018002932A1/es unknown
- 2018-10-19 EC ECSENADI201879073A patent/ECSP18079073A/es unknown
- 2018-11-14 CO CONC2018/0012295A patent/CO2018012295A2/es unknown
-
2021
- 2021-04-03 US US17/221,788 patent/US20210220453A1/en not_active Abandoned
- 2021-06-02 CL CL2021001441A patent/CL2021001441A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NI201800105A (es) | 2019-02-18 |
| CU20180127A7 (es) | 2019-08-06 |
| CO2018012295A2 (es) | 2019-04-30 |
| CN109310747A (zh) | 2019-02-05 |
| EP3442569A1 (en) | 2019-02-20 |
| CN116059330A (zh) | 2023-05-05 |
| MX2018012504A (es) | 2019-08-29 |
| KR20190039022A (ko) | 2019-04-10 |
| US20170296637A1 (en) | 2017-10-19 |
| CN109310747B (zh) | 2022-11-22 |
| SG11201808915YA (en) | 2018-11-29 |
| BR112018071108A2 (pt) | 2019-02-26 |
| AU2017248680A1 (en) | 2018-11-22 |
| CL2021001441A1 (es) | 2021-11-19 |
| US20210220453A1 (en) | 2021-07-22 |
| WO2017178660A1 (en) | 2017-10-19 |
| RU2018139865A (ru) | 2020-05-14 |
| CA3020856A1 (en) | 2017-10-19 |
| ECSP18079073A (es) | 2019-02-28 |
| CL2018002932A1 (es) | 2019-02-01 |
| US10973897B2 (en) | 2021-04-13 |
| JP2019513797A (ja) | 2019-05-30 |
| WO2017178660A9 (en) | 2017-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023015185A (es) | Degradadores de proteinas y usos de los mismos. | |
| EA201890640A1 (ru) | Рекомбинантные векторы, содержащие пептид 2а | |
| MX2021011167A (es) | Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso. | |
| EA201892250A1 (ru) | Вакцина против rsv | |
| CL2018001522A1 (es) | Focalización de péptidos para dirigir virus adenoasociados (aavs) | |
| PE20180317A1 (es) | Anticuerpos anti-tau y metodos de uso | |
| EA201990071A1 (ru) | Композиция пептидной вакцины | |
| BR112019007369A2 (pt) | anticorpos anti-lag-3 e métodos de uso dos mesmos | |
| PE20250415A1 (es) | Composiciones y metodos de inhibicion del masp-3 para el tratamiento de diversas enfermedades y trastornos | |
| DOP2016000051A (es) | Polipéptido para la escisión hidrolítica de la zearalenona y/o derivados de la zearalenona, polinucleótido aislado de la misma y poliéptido que contiene aditivo, uso y procedimiento de los mismos. | |
| CL2017001883A1 (es) | Compuestos antisenescentes y usos de los mismos | |
| BR112017009817A2 (pt) | anticorpos anti-il-1beta e métodos de utilização | |
| EA201692512A1 (ru) | Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки | |
| MX2020005555A (es) | Construcciones inmunogenicas de peptidos de tau. | |
| BR112017009790A2 (pt) | anticorpos direcionados ao anti-ang2 e métodos de uso | |
| AR101871A1 (es) | Composiciones de glicoconjugado inmunogénico / terapéutico y sus usos | |
| ES2722773T3 (es) | Polipéptidos de fHbp meningocócicos modificados | |
| BR112016016103A2 (pt) | Composição de antígenos micobacterianos | |
| BR112017018703A2 (pt) | peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno | |
| MX2021004356A (es) | Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas. | |
| AR095076A1 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| CO2017011431A2 (es) | Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina | |
| BR112017016110A2 (pt) | composições de imunoglobulina equina e usos para tratamento de doenças mediadas por filovírus | |
| PE20190104A1 (es) | Antigenos y anticuerpos de chagas y composiciones, metodos y usos de los mismos | |
| MX2018001298A (es) | Agente inductor de inmunidad. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |